Topics:
Thoracic Malignancies • Medical Oncology
What is your preferred systemic treatment for patients progressing during or soon after completion of consolidation durvalumab for unresectable NSCLC?
Answer from: Medical Oncologist at Community Practice
This is an excellent question for which (to my knowledge) no randomized prospective data is available. As this is a frequent clinical scenario, one would hope that investigators in the thoracic oncology field would perform such a study in the future. That being said, I can see the rationale for givi...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
If platinum resistant, I would offer docetaxel, ramucirumab, and pembrolizumab on clinical trial NCT04340882.